Reaction Details | |||
---|---|---|---|
Report a problem with these data | |||
Target | Serine/threonine-protein kinase mTOR | ||
Ligand | BDBM50433045 | ||
Substrate/Competitor | n/a | ||
Meas. Tech. | ChEMBL_955789 (CHEMBL2379606) | ||
Ki | 2.5±n/a nM | ||
Citation | Cheng, H; Hoffman, JE; Le, PT; Pairish, M; Kania, R; Farrell, W; Bagrodia, S; Yuan, J; Sun, S; Zhang, E; Xiang, C; Dalvie, D; Rahavendran, SV Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series. Bioorg Med Chem Lett23:2787-92 (2013) [PubMed] Article | ||
More Info.: | Get all data from this article, Assay Method | ||
Serine/threonine-protein kinase mTOR | |||
Name: | Serine/threonine-protein kinase mTOR | ||
Synonyms: | FK506-binding protein 12-rapamycin complex-associated protein 1 | FKBP12-rapamycin complex-associated protein | FRAP | FRAP 1 (mTOR) | FRAP1 | FRAP2 | MTOR | MTOR_HUMAN | Mammalian Target of Rapamycin (mTOR) | P42345 | RAFT1 | RAPT1 | Rapamycin and FKBP12 target 1 | Rapamycin target protein | Serine/threonine-protein kinase (mTOR) | mTORC2 | ||
Type: | Rapamycin target protein | ||
Mol. Mass.: | 288917.12 | ||
Organism: | Homo sapiens (Human) | ||
Description: | P42345 | ||
Residue: | 2549 | ||
Sequence: |
| ||
BDBM50433045 | |||
n/a | |||
Name | BDBM50433045 | ||
Synonyms: | CHEMBL2375964 | US8633204, 303 | ||
Type | Small organic molecule | ||
Emp. Form. | C22H26N6O4 | ||
Mol. Mass. | 438.4796 | ||
SMILES | COc1ccc(cn1)-c1cc2c(C)nc(N)nc2n([C@@H]2CC[C@@H](CC2)OCC(N)=O)c1=O |r,wD:19.20,22.27,(14.55,-30.27,;13.22,-29.49,;11.88,-30.26,;10.54,-29.49,;9.21,-30.26,;9.21,-31.79,;10.54,-32.57,;11.88,-31.8,;7.87,-32.55,;6.53,-31.77,;5.19,-32.55,;3.85,-31.78,;3.85,-30.24,;2.52,-32.55,;2.52,-34.1,;1.19,-34.87,;3.86,-34.87,;5.19,-34.1,;6.52,-34.88,;6.51,-36.41,;7.85,-37.18,;7.83,-38.73,;6.5,-39.49,;5.17,-38.71,;5.18,-37.18,;6.49,-41.03,;5.15,-41.79,;3.82,-41.01,;2.48,-41.77,;3.83,-39.47,;7.87,-34.1,;9.2,-34.88,)| | ||
Structure |